Scarica l'app Stockscreener
56.68
1.19%
-0.68
Dopo l'orario di chiusura:
56.68
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TVTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$57.36
Aprire:
$57.95
Volume 24 ore:
1.66M
Relative Volume:
0.80
Capitalizzazione di mercato:
$5.27B
Reddito:
$536.20M
Utile/perdita netta:
$-45.64M
Rapporto P/E:
-105.98
EPS:
-0.5348
Flusso di cassa netto:
$-28.94M
1 W Prestazione:
+2.18%
1M Prestazione:
-3.69%
6M Prestazione:
+88.74%
1 anno Prestazione:
+269.97%
Intervallo 1D:
$56.67
$59.09
Intervallo di 1 settimana:
$54.32
$60.00
Portata 52W:
$15.03
$60.10
Travere Therapeutics Inc Stock (TVTX) Company Profile
Nome
Travere Therapeutics Inc
Settore
Industria
Telefono
888-969-7879
Indirizzo
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
56.68 | 5.33B | 536.20M | -45.64M | -28.94M | -0.5348 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-14 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-10-31 | Reiterato | Citigroup | Buy |
| 2025-06-11 | Reiterato | Citigroup | Buy |
| 2025-06-11 | Ripresa | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-09 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-03-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-12-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-11-20 | Iniziato | Citigroup | Neutral |
| 2023-09-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Ripresa | Evercore ISI | Outperform |
| 2023-07-21 | Iniziato | JP Morgan | Overweight |
| 2023-06-07 | Ripresa | Piper Sandler | Neutral |
| 2023-05-22 | Iniziato | TD Cowen | Outperform |
| 2023-05-05 | Aggiornamento | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-21 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2022-12-14 | Iniziato | Stifel | Hold |
| 2022-12-05 | Iniziato | Wells Fargo | Overweight |
| 2022-09-21 | Iniziato | Bryan Garnier | Sell |
| 2022-07-14 | Ripresa | Canaccord Genuity | Buy |
| 2022-03-31 | Iniziato | Piper Sandler | Overweight |
| 2022-02-28 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-26 | Downgrade | Wedbush | Outperform → Neutral |
Mostra tutto
Travere Therapeutics Inc Borsa (TVTX) Ultime notizie
Travere Therapeutics Inc (TVTX) Cash Flow - TradingKey
Investigation launched into Travere Therapeutics' officers for possible self-dealing breaches - Pluang
TradingKey - TradingKey
Travere Therapeutics Inc (TVTX) Institutional Confidence - TradingKey
Travere Therapeutics (NASDAQ:TVTX): High Growth Momentum Stock with Breakout Setup - ChartMill
Travere Therapeutics Inc (TVTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Travere Therapeutics Inc (TVTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease - Stocktwits
TVTX|Travere Therapeutics Inc|Price:57.370|Chg%:+0.690 - TradingKey
Travere Therapeutics Inc (TVTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment - Stocktwits
Travere Therapeutics (TVTX) Gets a Buy from Guggenheim - The Globe and Mail
Travere Therapeutics, Inc. Stock 12‑Month Price Target Raised to $58.71, Implies 4% Upside - TradingView
TVTX|Travere Therapeutics Inc|Price:56.670|Chg%:+0.410 - TradingKey
Why (TVTX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
ETFs Investing in Travere Therapeutics, Inc. Stocks - TradingView
RTRX5376243 Bond Profile — Key Metrics - TradingView
Exploring High Growth Tech Stocks In The US For July 2026 - simplywall.st
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
Law firm probes Travere Therapeutics officers f... - Pluang
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: Pediatrix Medical Group (MD) and Travere Therapeutics (TVTX) - The Globe and Mail
RTRX6388605 Bond Risk Profile - TradingView
RTRX6388605 Bond Profile — Key Metrics - TradingView
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Travere Therapeutics Accounting Chief Sandra Calvin to Retire in 2027 - Moomoo
Travere Therapeutics, Inc. Files Form 8-K with SEC: Key Details on Company and Stock Listing for July 2026 - Minichart
Sandra Calvin to Retire as Travere Therapeutics CAO; John Torell Named Successor - TradingView
Travere Therapeutics (NASDAQ: TVTX) plans CAO transition as Sandra Calvin retires - Stock Titan
Travere Therapeutics Inc. (TVTX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
US FDA approves Vera's kidney disease drug - Reuters
Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib - Macau Business
Travere Therapeutics, Inc. Actuals & Estimates (NASDAQ:TVTX) - TradingView
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy - AOL.com
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress - AOL.com
Will Travere’s Removal From Key Russell Value Indices Change Travere Therapeutics' (TVTX) Narrative? - simplywall.st
Travere Therapeutics: Filspari Is Becoming A Rare Kidney Disease Platform (NASDAQ:TVTX) - Seeking Alpha
Travere Therapeutics Receives Notice of Allowance from the U.S. P - The National Law Review
Travere Therapeutics, Inc.(NasdaqGM: TVTX) dropped from Russell 2000 Value Benchmark - marketscreener.com
Understanding Momentum Shifts in (TVTX) - Stock Traders Daily
Travere Therapeutics, Inc.(NasdaqGM:TVTX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Enterprise value to revenue forward of Travere Therapeutics, Inc. – NASDAQ:TVTX - TradingView
Price to earnings forward of Travere Therapeutics, Inc. – NASDAQ:TVTX - TradingView
Enterprise value to EBITDA forward of Travere Therapeutics, Inc. – NASDAQ:TVTX - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Travere Therapeutics Inc Azioni (TVTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):